The use of targeted therapies and selection of the optimal treatment sequence in heterogeneous population of patients with metastatic kidney cancer. Results of retrospective study
https://doi.org/10.17650/1726-9776-2016-12-3-52-57
Abstract
Renal cancer is one of the most rapidly spreading diseases in the world. As you know, a few years ago, overall survival of patients with metastatic renal cell carcinoma (mRCC) was disappointing: median overall survival rarely exceeded 13 months, while 5-year survival rate was less than 5 %. Immunotherapy with interferon-alpha and interleukins demonstrated low efficiency. Appearance of targeted therapies for the treatment of mRCC significantly increased the duration and quality of life of patients receiving drug treatment. Nowadays due to this methodology and guided by the results of randomized clinical trials we can choose an optimal sequence of therapy and control the disease in three consecutive lines for about 30 months. In this article we would like to share an experience of the use of targeted therapies in the Saint Petersburg City Clinical Oncology Dispensary in patients with clear-cell mRCC.
About the Authors
P. S. Borisov
Saint Petersburg State Budgetary Healthcare Institution “City Clinical Oncological Dispensary”
Russian Federation
3/5 2nd Berezovaya alleya, Saint Petersburg, 197022
Russian Federation
3/5 2nd Berezovaya alleya, Saint Petersburg, 197022
M. I. Shkol’nik
Federal State Budgetary Institution “Russian Scientific Center of Radiology and Surgical Technologies”, Russian Ministry of Health
Russian Federation
Competing Interests: 70 Leningradskaya St., Pesochnyy Suttlement, Saint Petersburg, 197758
Russian Federation
Competing Interests: 70 Leningradskaya St., Pesochnyy Suttlement, Saint Petersburg, 197758
R. V. Orlova
Federal State Budgetary Educational Institution of Higher Professional Education “Saint-Petersburg State University”
Russian Federation
7 Universitetskaya Pr., Saint Petersburg, 199043
Russian Federation
7 Universitetskaya Pr., Saint Petersburg, 199043
P. A. Karlov
Saint Petersburg State Budgetary Healthcare Institution “City Clinical Oncological Dispensary”
Russian Federation
3/5 2nd Berezovaya alleya, Saint Petersburg, 197022
Russian Federation
3/5 2nd Berezovaya alleya, Saint Petersburg, 197022
References
1. Simard E.P., Ward E.M., Siegel R., Jemal A. Cancers with Increasing Incidence Trends in the United States: 1999 through 2008. CA Cancer J Clin 2012;62(2): 118–28. 1.DOI: 10.3322/caac.20141.
2. Злокачественные новообразования в России в 2013 году (заболеваемость и смертность). Под ред. А.Д. Каприна, В.В. Старинского, Г.В. Петровой. М., 2015. [Malignant tumors in Russia in 2013 (morbidity and fatality). Ed. by: А.D. Kaprin, V.V. Starinskiy, G.V. Petrova. Мoscow, 2015. (In Russ.)].
3. Keane T., Gilliatt D. Current and future trends in treatment of renal cancer. Eur Urol 2007;(Suppl 6):374–84.
4. Cohen H.T., McCovern F.J. Renal-Cell Carcinoma. N. Engl J Med 2005;353(23):2477–90.
5. Motzer R.J., Bacik J., Murphy B.A. Interferon-alfa as a comparative treatment for clinical trials of new therapies against advanced renal cell carcinoma. J Clin Oncol 2002;20(1):289–96.
6. Coppin C., Porzsolt F., Awa A. et al. Immunotherapy for advanced renal cell cancer. Cochrane Database Syst Rev 2005;(1):CD001425.
7. Negrier S., Perol D., Ravaud A. et al. Medroxyprogesterone, interferon alfa-2a, interleukin 2, or combination of both cytokines in patients with metastatic renal carcinoma of intermediate prognosis: results of a randomized controlled trial. Cancer 2007;110(11):2468–77.
8. Motzer R.J., Masumdar M., Murphy B.A. et al. Survival and prognostic stratification of 670 patients with advanced renal cell carcinoma. J Clin Oncol 1999;17(8):2530–40.
9. Алексеев Б.Я., Калпинский А.С. Эффективность применения таргетной терапии в гетерогенной популяции больных метастатическим раком почки. Онкоурология 2012;8(3): 37–42. [Аlekseev B.Ya., Kalpinskiy А.S. Target therapy efficiency in the geterogenous population of patients with metastatic kidney cancer. Onkourologiya = Оncourology 2012;8(3):37–42. (In Russ.)].
Review
For citations:
Borisov P.S., Shkol’nik M.I., Orlova R.V., Karlov P.A. The use of targeted therapies and selection of the optimal treatment sequence in heterogeneous population of patients with metastatic kidney cancer. Results of retrospective study. Cancer Urology. 2016;12(3):52-57. https://doi.org/10.17650/1726-9776-2016-12-3-52-57
Views:
1221
Email this article 